Pharmacopeia Drug Discovery Inc. could receive up to $189 million in a deal with Wyeth Pharmaceuticals to develop compounds inhibiting JAK3, a target that has gained interest over the last few months in the area of inflammatory disease. (BioWorld Today) Read More